Zobrazeno 1 - 10
of 107
pro vyhledávání: '"JUNKO HAMAMOTO"'
Autor:
Toshiki Ebisudani, Junko Hamamoto, Kazuhiro Togasaki, Akifumi Mitsuishi, Kai Sugihara, Taro Shinozaki, Takahiro Fukushima, Kenta Kawasaki, Takashi Seino, Mayumi Oda, Hikaru Hanyu, Kohta Toshimitsu, Katsura Emoto, Yuichiro Hayashi, Keisuke Asakura, Todd A. Johnson, Hideki Terai, Shinnosuke Ikemura, Ichiro Kawada, Makoto Ishii, Tomoyuki Hishida, Hisao Asamura, Kenzo Soejima, Hidewaki Nakagawa, Masayuki Fujii, Koichi Fukunaga, Hiroyuki Yasuda, Toshiro Sato
Publikováno v:
Cell Reports, Vol 42, Iss 3, Pp 112212- (2023)
Summary: Human lung cancer is a constellation of tumors with various histological and molecular properties. To build a preclinical platform that covers this broad disease spectrum, we obtained lung cancer specimens from multiple sources, including sp
Externí odkaz:
https://doaj.org/article/9ae31700ae9f4c67b5d8de1d1a09cd18
Autor:
Aoi Kuroda, Ahmed E. Hegab, Gao Jingtao, Shuji Yamashita, Nobuyuki Hizawa, Tohru Sakamoto, Hideyasu Yamada, Satoshi Suzuki, Makoto Ishii, Ho Namkoong, Takanori Asakura, Mari Ozaki, Hiroyuki Yasuda, Junko Hamamoto, Shizuko Kagawa, Kenzo Soejima, Tomoko Betsuyaku
Publikováno v:
Respiratory Research, Vol 18, Iss 1, Pp 1-18 (2017)
Abstract Background Aldehyde dehydrogenases (ALDHs) play a major role in detoxification of aldehydes. High expression of ALDHs is a marker for stem cells of many organs including the lungs. A common polymorphism in ALDH2 gene (ALDH2*2) results in ina
Externí odkaz:
https://doaj.org/article/99dab1cd5f8040c1aa344f4e038ef6c9
Autor:
Kenzo Soejima, Katsuhiko Naoki, Ichiro Kawada, Shinnosuke Ikemura, Hideki Terai, Tadashi Manabe, Keita Masuzawa, Junko Hamamoto, Tetsuo Tani, Keigo Kobayashi, Hiroyuki Yasuda, Ayano Oashi
Figure S1 Synergistic efficacy of afatinib and cetuximab combination therapy Figure S2 Efficacy of EGFR-TKIs and cetuximab combination therapy Figure S3 Effect of EGFR tyrosine kinase inhibitors on EGFR monomer dimer equilibrium Figure S4 Dimerizatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4775540df998242f3d73d87645a5dc87
https://doi.org/10.1158/1535-7163.22506109
https://doi.org/10.1158/1535-7163.22506109
Autor:
Koichi Fukunaga, Kenzo Soejima, Hiroyuki Yasuda, Sumio Ohtsuki, Yukio Suzuki, Osamu Takeuchi, Yusuke Suzuki, Ichiro Kawada, Sohei Nakayama, Shinnosuke Ikemura, Keita Masuzawa, Keigo Kobayashi, Satoshi Kuronuma, Tadashi Manabe, Takeshi Masuda, Katsura Emoto, Junko Hamamoto, Hideki Terai
The combination of osimertinib and celastrol demonstrated a synergistic anti-proliferative effect in PC9 cells and H1975 cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beb4412be1a31ac1333d84115cf8d640
https://doi.org/10.1158/1541-7786.22526495
https://doi.org/10.1158/1541-7786.22526495
Autor:
Tomoko Betsuyaku, Katsuhiko Naoki, Ryosuke Satomi, Satoshi Yoda, Takashi Sato, Shinnosuke Ikemura, Keiko Ohgino, Kota Ishioka, Daisuke Arai, Junko Hamamoto, Sohei Nakayama, Hiroyuki Yasuda, Kenzo Soejima, Hideki Terai
Supplementary Figure S3 - PDF file 139K,The relative expression profiles of mRNA of FGFs by microarray analysis in PC9 GR, PC9 gr1 and PC9 gr3 cells normalized to mRNA extracted from PC9 na cells. None of FGFs other than FGF2 was elevated in gefitini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a96ff9bac07c9cb74634b3bd0add81b7
https://doi.org/10.1158/1541-7786.22509946.v1
https://doi.org/10.1158/1541-7786.22509946.v1
Autor:
Kenzo Soejima, Tomoko Betsuyaku, Yuichiro Hayashi, Katsuhiko Naoki, Ichiro Kawada, Masayoshi Miyawaki, Keiko Ohgino, Kota Ishioka, Daisuke Arai, Aoi Kuroda, Junko Hamamoto, Hiroyuki Yasuda, Tetsuo Tani
Irreversible resistance of H3122-AR cells to alectinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06a7102b54bb143082b53df7a013bb2a
https://doi.org/10.1158/1535-7163.22499890
https://doi.org/10.1158/1535-7163.22499890
Autor:
Kenzo Soejima, Tomoko Betsuyaku, Yuichiro Hayashi, Katsuhiko Naoki, Ichiro Kawada, Masayoshi Miyawaki, Keiko Ohgino, Kota Ishioka, Daisuke Arai, Aoi Kuroda, Junko Hamamoto, Hiroyuki Yasuda, Tetsuo Tani
Alectinib is a highly selective ALK inhibitor and shows promising efficacy in non–small cell lung cancers (NSCLC) harboring the EML4-ALK gene rearrangement. The precise mechanism of acquired resistance to alectinib is not well defined. The purpose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbad99840c1940584567a52032bceac9
https://doi.org/10.1158/1535-7163.c.6536290
https://doi.org/10.1158/1535-7163.c.6536290
Autor:
Koichi Fukunaga, Kenzo Soejima, Hiroyuki Yasuda, Sumio Ohtsuki, Yukio Suzuki, Osamu Takeuchi, Yusuke Suzuki, Ichiro Kawada, Sohei Nakayama, Shinnosuke Ikemura, Keita Masuzawa, Keigo Kobayashi, Satoshi Kuronuma, Tadashi Manabe, Takeshi Masuda, Katsura Emoto, Junko Hamamoto, Hideki Terai
Figure S1. Overview of the CRISPR/Cas9 screen performed in EGFR mutation positive NSCLC PC9 cells. Figure S2. Cell viability assay of cytotoxic agents or ALK-TKI in SHOC2-depleted cells. Figure S3. Supplementary data for domain analysis. Figure S4. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cd85cabe3251f7f3766fd74137719e1
https://doi.org/10.1158/1541-7786.22526504.v1
https://doi.org/10.1158/1541-7786.22526504.v1
Autor:
Koichi Fukunaga, Kenzo Soejima, Hiroyuki Yasuda, Sumio Ohtsuki, Yukio Suzuki, Osamu Takeuchi, Yusuke Suzuki, Ichiro Kawada, Sohei Nakayama, Shinnosuke Ikemura, Keita Masuzawa, Keigo Kobayashi, Satoshi Kuronuma, Tadashi Manabe, Takeshi Masuda, Katsura Emoto, Junko Hamamoto, Hideki Terai
EGFR mutation-positive patients with non–small cell lung cancer (NSCLC) respond well to treatment with EGFR–tyrosine kinase inhibitors (EGFR–TKI); however, treatment with EGFR–TKIs is not curative, owing to the presence of residual cancer cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e22cbbc37877ea3df7bb5e3f24ca074d
https://doi.org/10.1158/1541-7786.c.6545117.v1
https://doi.org/10.1158/1541-7786.c.6545117.v1
Autor:
Kenzo Soejima, Katsuhiko Naoki, Ichiro Kawada, Shinnosuke Ikemura, Hideki Terai, Tadashi Manabe, Keita Masuzawa, Junko Hamamoto, Tetsuo Tani, Keigo Kobayashi, Hiroyuki Yasuda, Ayano Oashi
EGFR-mutated lung cancer is a significant subgroup of non–small cell lung cancer. To inhibit EGFR-mediated signals, multiple EGFR tyrosine kinase inhibitors (EGFR-TKI) have been developed; however, approximately one third of patients with EGFR-muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::964378d7ff7f480eacf37b1826ba88d8
https://doi.org/10.1158/1535-7163.c.6538294.v1
https://doi.org/10.1158/1535-7163.c.6538294.v1